Key Insights

Highlights

Success Rate

97% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

2.6%

1 terminated out of 39 trials

Success Rate

96.8%

+10.3% vs benchmark

Late-Stage Pipeline

26%

10 trials in Phase 3/4

Results Transparency

20%

6 of 30 completed with results

Key Signals

6 with results97% success

Data Visualizations

Phase Distribution

35Total
Not Applicable (11)
P 1 (7)
P 2 (7)
P 3 (6)
P 4 (4)

Trial Status

Completed30
Unknown4
Active Not Recruiting2
Recruiting1
Terminated1
Not Yet Recruiting1

Trial Success Rate

96.8%

Benchmark: 86.5%

Based on 30 completed trials

Clinical Trials (39)

Showing 20 of 20 trials
NCT05032976Active Not Recruiting

Korea Comirnaty Post-marketing Surveillance

NCT06179446Phase 1Completed

A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza

NCT01306006Phase 4Completed

The Effect on Overall Mortality of a National Policy of Limiting Measles Vaccination to Children Below 12 Months of Age

NCT06437834Not ApplicableCompletedPrimary

Increasing Men's Engagement in Preventive Healthcare Through an Enhanced Cocoon Vaccination Strategy

NCT06470919Not ApplicableCompletedPrimary

The Next Generation Vaccine Card: Innovative Technology to Improve Vaccine Equity in Rural and Urban Settings in East Africa

NCT02242968CompletedPrimary

Screening of Volunteers for Clinical Trials of Investigational or Licensed Vaccines or Antiviral Products

NCT05284097Phase 2Completed

Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study

NCT06745635Not ApplicableNot Yet RecruitingPrimary

A Multifaceted Intervention on Reducing Immunization Errors

NCT05586204Not ApplicableCompleted

Boost Intentions and Facilitate Action to Promote COVID-19 Booster Take-up

NCT05586165Not ApplicableCompleted

Effects of Prompt to Bundle COVID-19 Booster and Flu Shot

NCT05586178Not ApplicableCompleted

Information Provision and Consistency Framing to Increase COVID-19 Booster Uptake

NCT05993325Phase 3Active Not Recruiting

Immunogenicity and Safety of AdCLD-CoV19-1 OMI As a Booster: a COVID-19 Preventive Vaccine in Healthy Volunteers

NCT05576623Phase 1Completed

Safety and Immunogenicity of AdCLD-CoV19-1 OMI as a Booster: A SARS-CoV-2 (COVID-19) Preventive Vaccine

NCT06259487Not ApplicableRecruiting

Coordinated Vaccination Against RSV and Influenza in Patients With Chronic Heart Failure and Its Impact on Prognosis.

NCT05593042Phase 2Completed

Immunogenicity Evaluation of Omicron Variant-based Vaccine and a Trivalent Vaccine in Adults Against COVID-19 in Chile

NCT05520970Phase 2Terminated

Safety and Immunogenicity of COVID-19 Vaccine, AdCLD-CoV19-1

NCT05711810Phase 4Completed

Medicine-induced Cardiac Hemodialysis on COVID-19

NCT04651790Phase 3Completed

Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against COVID-19 in Adults

NCT00688870Phase 3CompletedPrimary

Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered to Infants in Taiwan

NCT05494047Phase 3Unknown

Phase Ⅲ, Clinical Trial to Compare an Inactivated Quadrivalent Influenza Vaccine and a Licensed Vaccine in Chile

Scroll to load more

Research Network

Activity Timeline